The number of clinical trials of drugs in the Russian Federation is stable and is not decreasing. This is reported by TASS with reference to the press service of the Ministry of Health of the Russian Federation.
The RBC publication previously reported, referring to the bulletin of the Association of Clinical Research Organizations (ACRO), that for six months of this year in Russia, almost 50% of previously planned trials of innovative drugs were not implemented or were suspended. The Association of Clinical Research Organizations (ACRO) is also confident that the number of frozen clinical trials is going to increase if the geopolitical situation remains the same.
“The total number of clinical trials conducted in the Russian Federation, including international and local ones, is stable and does not decrease. The findings of a comprehensive analysis of the main general economic trends in the economies of different countries, regional potentials, and the development of demographic situations allow us to conclude that the Russian market for clinical trials of medicines retains its attractiveness and has real development prospects,” the message reads.
As explained in the Ministry of Health, a total of 577 trial permits were issued from January 1 to September 30, 2022. More than 75% of all new research has traditionally been initiated in the leading therapeutic areas: oncology, pulmonology, diseases of the cardiovascular system, endocrinology, and rheumatology. The growth is due, in particular, to the increasing activity of Russian pharmaceutical manufacturers.
In addition, this year has seen 17% increase in the number of clinical trials conducted by Russian developers of drugs used in the so-called breakthrough therapy, including the treatment of spinal muscular atrophy, hemophilia, etc., according to the Ministry.
Russia’s pharmaceutical companies have increased the number of clinical trials by almost a third, according to the earlier report of the Ministry of Industry and Trade.
